Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Medicure Inc (OP: MCUJF )

0.6755 UNCHANGED
Streaming Delayed Price Updated: 11:35 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.6755
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.6755
Today's Range 0.6755 - 0.6755
52wk Range 0.5792 - 1.170
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Medicure Reports Financial Results For Quarter Ended September 30, 2024
Via ACCESSWIRE
Medicure to Present Financial Results on November 26, 2024 Call at 8:30 AM ET for Quarter Ended September 30, 2024 and Announces Resignation of Board Member
Via ACCESSWIRE

Performance

YTD
-28.95%
-28.95%
1 Month
+7.22%
+7.22%
3 Month
-7.91%
-7.91%
6 Month
-9.93%
-9.93%
1 Year
-39.14%
-39.14%

More News

Read More
Medicure Announces Positive Settlement of Product Development and Supply Contracts
Via ACCESSWIRE
Medicure Reports Financial Results for Quarter Ended June 30, 2024
Via ACCESSWIRE
Medicure Announces Signing of Asset Purchase Agreement with CanAm Bioresearch Inc. for Acquisition of Intellectual Property
Via ACCESSWIRE
Medicure Reports Financial Results for Quarter Ended March 31, 2024 and Annual General Meeting Director Election Results
Via ACCESSWIRE
Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
Via ACCESSWIRE
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2023
Via ACCESSWIRE
Medicure To Present Financial Results on April 9, 2024 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2023
Via ACCESSWIRE
Medicure Announces New Partnership Through Its Marley Drug Subsidiary to Provide Brenzavvy(R) as an Affordable Medication for Americans with Type 2 Diabetes
Via ACCESSWIRE
Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease
Via ACCESSWIRE
Medicure Reports Financial Results for Quarter Ended September 30, 2023
Via ACCESSWIRE
Medicure Reiterates its Commitment to Providing Exceptional Access to its Branded Pitavastatin (Zypitamag) to People Living With HIV
Via ACCESSWIRE
Medicure Reports Financial Results For Quarter Ended June 30, 2023
Via ACCESSWIRE
Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023
Via ACCESSWIRE
Medicure Reports Financial Results for Quarter Ended March 31, 2023
Via ACCESSWIRE
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2022
Via ACCESSWIRE
Medicure To Present Financial Results on April 10, 2023 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2022
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.